Skip to main content
Top
Published in: European Journal of Epidemiology 3/2017

01-03-2017 | CANCER

Myocardial infarction and future risk of cancer in the general population—the Tromsø Study

Authors: Ludvig B. Rinde, Birgit Småbrekke, Erin M. Hald, Ellen E. Brodin, Inger Njølstad, Ellisiv B. Mathiesen, Maja-Lisa Løchen, Tom Wilsgaard, Sigrid K. Brækkan, Anders Vik, John-Bjarne Hansen

Published in: European Journal of Epidemiology | Issue 3/2017

Login to get access

Abstract

The association between myocardial infarction (MI) and future risk of incident cancer is scarcely investigated. Therefore, we aimed to study the risk of cancer after a first time MI in a large cohort recruited from a general population. Participants in a large population-based study without a previous history of MI or cancer (n = 28,763) were included and followed from baseline to date of cancer, death, migration or study end. Crude incidence rates (IRs) and hazard ratios (HRs) for cancer after MI were calculated. During a median follow-up of 15.7 years, 1747 subjects developed incident MI, and of these, 146 suffered from a subsequent cancer. In the multivariable-adjusted model (adjusted for age, sex, BMI, systolic blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical activity and education level), MI patients had 46% (HR 1.46; 95% CI: 1.21–1.77) higher hazard ratio of cancer compared to those without MI. The increased cancer incidence was highest during the first 6 months after the MI, with a 2.2-fold higher HR (2.15; 95% CI: 1.29–3.58) compared with subjects without MI. After a 2-year period without higher incidence rate, MI patients displayed 60% (HR 1.60; 95% CI: 1.27–2.03) higher HR of future cancer more than 3 years after the event. The increased IRs were higher in women than men. Patients with MI had a higher short- and long-term incidence rate of cancer compared to subjects without MI. Our findings suggest that occult cancer and shared risk factors of MI and cancer may partly explain the association.
Appendix
Available only for authorised users
Literature
2.
go back to reference Pehrsson SK, Linnersjo A, Hammar N. Cancer risk of patients with ischaemic syndromes. J Intern Med. 2005;258(2):124–32.PubMedCrossRef Pehrsson SK, Linnersjo A, Hammar N. Cancer risk of patients with ischaemic syndromes. J Intern Med. 2005;258(2):124–32.PubMedCrossRef
3.
go back to reference Dreyer L, Olsen JH. Cancer risk of patients discharged with acute myocardial infarct. Epidemiology. 1998;9(2):178–83.PubMedCrossRef Dreyer L, Olsen JH. Cancer risk of patients discharged with acute myocardial infarct. Epidemiology. 1998;9(2):178–83.PubMedCrossRef
4.
5.
go back to reference Naschitz JE, Yeshurun D, Abrahamson J, Eldar S, Chouri H, Kedar S, et al. Ischemic heart disease precipitated by occult cancer. Cancer. 1992;69(11):2712–20.PubMedCrossRef Naschitz JE, Yeshurun D, Abrahamson J, Eldar S, Chouri H, Kedar S, et al. Ischemic heart disease precipitated by occult cancer. Cancer. 1992;69(11):2712–20.PubMedCrossRef
6.
go back to reference Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 Surgeon General’s report: “The health consequences of smoking–50 years of progress”: a paradigm shift in cancer care. Cancer. 2014;120(13):1914–6.PubMedCrossRef Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 Surgeon General’s report: “The health consequences of smoking–50 years of progress”: a paradigm shift in cancer care. Cancer. 2014;120(13):1914–6.PubMedCrossRef
7.
go back to reference Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–9.PubMedCrossRef Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–9.PubMedCrossRef
8.
go back to reference Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3(9):565–74.PubMedCrossRef Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3(9):565–74.PubMedCrossRef
9.
go back to reference Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–29.PubMedPubMedCentralCrossRef Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–29.PubMedPubMedCentralCrossRef
10.
go back to reference Morganti M, Carpi A, Nicolini A, Gorini I, Glaviano B, Fini M, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother. 2002;56(7):317–24.PubMedCrossRef Morganti M, Carpi A, Nicolini A, Gorini I, Glaviano B, Fini M, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother. 2002;56(7):317–24.PubMedCrossRef
11.
go back to reference Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 2001;947:271–93.PubMedCrossRef Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci. 2001;947:271–93.PubMedCrossRef
12.
go back to reference Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81.PubMedCrossRef Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81.PubMedCrossRef
13.
go back to reference Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.PubMedCrossRef Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.PubMedCrossRef
14.
go back to reference Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromso study. Int J Epidemiol. 2012;41(4):961–7.PubMedCrossRef Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromso study. Int J Epidemiol. 2012;41(4):961–7.PubMedCrossRef
17.
go back to reference Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.PubMedCrossRef Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.PubMedCrossRef
18.
go back to reference Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.PubMedCrossRef Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.PubMedCrossRef
19.
go back to reference Zoller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer. 2012;48(1):121–8.PubMedCrossRef Zoller B, Ji J, Sundquist J, Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer. 2012;48(1):121–8.PubMedCrossRef
20.
go back to reference Hansen ES. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis–a review of the epidemiological evidence. Mutat Res. 1990;239(3):163–79. Hansen ES. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis–a review of the epidemiological evidence. Mutat Res. 1990;239(3):163–79.
21.
go back to reference Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519.PubMedPubMedCentralCrossRef Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519.PubMedPubMedCentralCrossRef
22.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.PubMedCrossRef Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.PubMedCrossRef
23.
24.
go back to reference Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912–7.PubMedCrossRef Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912–7.PubMedCrossRef
25.
go back to reference Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635–41.PubMedCrossRef Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332(10):635–41.PubMedCrossRef
26.
go back to reference Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia. Haematologica. 1997;82(1):96–100.PubMed Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia. Haematologica. 1997;82(1):96–100.PubMed
27.
go back to reference Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematol Am Soc Hematol Educ Program. 2007;2007(1):127–35. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematol Am Soc Hematol Educ Program. 2007;2007(1):127–35.
28.
go back to reference Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143(3):321–35.PubMedCrossRef Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143(3):321–35.PubMedCrossRef
29.
go back to reference de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol. 2007;44(2):106–13.PubMedCrossRef de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol. 2007;44(2):106–13.PubMedCrossRef
31.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef
33.
go back to reference Erichsen R, Svaerke C, Sorensen HT, Sandler RS, Baron JA. Risk of colorectal cancer in patients with acute myocardial infarction and stroke: a nationwide cohort study. Cancer Epidemiol Biomark Prev. 2013;22(11):1994–9.CrossRef Erichsen R, Svaerke C, Sorensen HT, Sandler RS, Baron JA. Risk of colorectal cancer in patients with acute myocardial infarction and stroke: a nationwide cohort study. Cancer Epidemiol Biomark Prev. 2013;22(11):1994–9.CrossRef
34.
go back to reference Reicher-Reiss H, Jonas M, Goldbourt U, Boyko V, Modan B. Selectively increased risk of cancer in men with coronary heart disease. Am J Cardiol. 2001;87(4):459–62.PubMedCrossRef Reicher-Reiss H, Jonas M, Goldbourt U, Boyko V, Modan B. Selectively increased risk of cancer in men with coronary heart disease. Am J Cardiol. 2001;87(4):459–62.PubMedCrossRef
35.
go back to reference Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.PubMedCrossRef Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.PubMedCrossRef
36.
go back to reference Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.PubMedCrossRef Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.PubMedCrossRef
37.
go back to reference Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.PubMedCrossRef Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.PubMedCrossRef
38.
go back to reference Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014;32(28):3177–83.PubMedCrossRef Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014;32(28):3177–83.PubMedCrossRef
39.
go back to reference Cardwell CR, Mc Menamin U, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomark Prev. 2015;24(5):833–41.CrossRef Cardwell CR, Mc Menamin U, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomark Prev. 2015;24(5):833–41.CrossRef
40.
go back to reference Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–94.PubMedCrossRef Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–94.PubMedCrossRef
41.
go back to reference Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer: a population-based case-control study. Prostate. 2011;71(16):1818–24.PubMedCrossRef Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer: a population-based case-control study. Prostate. 2011;71(16):1818–24.PubMedCrossRef
43.
go back to reference Ravnskov U, Rosch PJ, McCully KS. Statins do not protect against cancer: quite the opposite. J Clin Oncol. 2015;33(7):810–1.PubMedCrossRef Ravnskov U, Rosch PJ, McCully KS. Statins do not protect against cancer: quite the opposite. J Clin Oncol. 2015;33(7):810–1.PubMedCrossRef
44.
go back to reference Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077–80.PubMedCrossRef Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077–80.PubMedCrossRef
45.
go back to reference Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169–73.PubMedCrossRef Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169–73.PubMedCrossRef
Metadata
Title
Myocardial infarction and future risk of cancer in the general population—the Tromsø Study
Authors
Ludvig B. Rinde
Birgit Småbrekke
Erin M. Hald
Ellen E. Brodin
Inger Njølstad
Ellisiv B. Mathiesen
Maja-Lisa Løchen
Tom Wilsgaard
Sigrid K. Brækkan
Anders Vik
John-Bjarne Hansen
Publication date
01-03-2017
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 3/2017
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-017-0231-5

Other articles of this Issue 3/2017

European Journal of Epidemiology 3/2017 Go to the issue